{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:10:53Z","timestamp":1790392253445,"version":"4.1.0"},"reference-count":25,"publisher":"The Endocrine Society","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Beyond HbA1c, continuous glucose monitoring (CGM) is now widely used in clinical practice, providing more detailed information about glycemic control. However, its ability to predict long-term microvascular outcomes in type 1 diabetes remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between CGM-derived glucometrics and the 5-year incidence of microvascular complications, providing longitudinal real-world evidence in adults with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Longitudinal real-world cohort study with 5-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Tertiary referral center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Two hundred forty-six adults with type 1 diabetes (median age 40 [28-53] years, diabetes duration 24 [13-33] years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>No interventional treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure<\/jats:title>\n                    <jats:p>Composite microvascular endpoint including nephropathy (persistent albuminuria \u226520\u2005\u00b5g\/min, estimated glomerular filtration rate &amp;lt;60\u2005mL\/min\/1.73\u2005m2, and\/or renin\u2013angiotensin\u2013aldosterone system inhibitor use for albuminuria), severe retinopathy (proliferative retinopathy, maculopathy, and\/or blindness), and peripheral neuropathy (monofilament score &amp;lt;6\/6 and\/or abnormal nerve conduction).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HbA1c decreased from 7.6% (59\u2005mmol\/mol) to 7.2% (55\u2005mmol\/mol), and time in range (TIR, 70-180\u2005mg\/dL) increased from 50 \u00b1 14% to 61 \u00b1 15%. All CGM-derived metrics (TIR, mean glucose, glucose management indicator) were associated with the composite endpoint. In this longitudinal real-world cohort, a \u226510% decrease in TIR was associated with higher complication rates (33.3%) compared with a stable TIR (7.9%) or \u226510% increase (15.0%) (P = .011). In multivariable analyses adjusted for age and baseline TIR, change in TIR (\u0394TIR) remained independently associated with outcomes. Body mass index and systolic blood pressure were not significant. Models incorporating glucometrics and age showed acceptable discriminative performance (area under the curves 0.757-0.787).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Continuous glucose monitoring\u2013derived glucometrics were associated with the 5-year incidence of microvascular complications in this real-world cohort, with \u0394TIR potentially providing additional prognostic information beyond glycated hemoglobin (HbA1c). Further validation is needed before routine clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgag380","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:20Z","timestamp":1789474040000},"source":"Crossref","is-referenced-by-count":1,"title":["Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study"],"prefix":"10.1210","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1109-5121","authenticated-orcid":false,"given":"Amber","family":"Sabbe","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-9086","authenticated-orcid":false,"given":"Niels","family":"Bochanen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Van den Broucke","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Antwerp , 2610 Wilrijk ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Mihalj\u010di\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Antwerp , 2610 Wilrijk ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Bigar\u00e9","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Antwerp , 2610 Wilrijk ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-2901","authenticated-orcid":false,"given":"Kristof","family":"Van Dessel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Bouziotis","sequence":"additional","affiliation":[{"name":"Clinical Trial Center (CTC), CRC Antwerp, Antwerp University Hospital, University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-7648","authenticated-orcid":false,"given":"Kristien","family":"Ledeganck","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, University of Antwerp , 2610 Wilrijk ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-2210","authenticated-orcid":false,"given":"Eveline","family":"Dirinck","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bolsens","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-6715","authenticated-orcid":false,"given":"Jolien","family":"De Meulemeester","sequence":"additional","affiliation":[{"name":"Endocrinology, University Hospitals Leuven and KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-4561","authenticated-orcid":false,"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[{"name":"Endocrinology, University Hospitals Leuven and KU Leuven , 3000 Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3203","authenticated-orcid":false,"given":"Christophe","family":"De Block","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, Endocrinology-Diabetology, Antwerp University Hospital and University of Antwerp , 2650 Edegem ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"issue":"14","key":"2026092511121457600_dgag380-B1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"2026092511121457600_dgag380-B2","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1210\/clinem\/dgab688","article-title":"Relationship between time in range, glycemic variability, HbA1c, and complications in adults with type 1 diabetes Mellitus","volume":"107","author":"El Malahi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026092511121457600_dgag380-B3","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert Committee","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"2026092511121457600_dgag380-B4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s13300-019-0619-1","article-title":"A view beyond HbA1c: role of continuous glucose monitoring","volume":"10","author":"Chehregosha","year":"2019","journal-title":"Diabetes Ther"},{"issue":"1","key":"2026092511121457600_dgag380-B5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2337\/dc13-2113","article-title":"Kidney disease and related findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study","volume":"37","author":"de Boer","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"2026092511121457600_dgag380-B6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2213-8587(14)70155-X","article-title":"Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the diabetes control and complications trial and epidemiology of diabetes interventions and complications study","volume":"2","author":"DCCT\/EDIC research group","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026092511121457600_dgag380-B7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2337\/dc18-2308","article-title":"Risk factors for retinopathy in type 1 diabetes: the DCCT\/EDIC study","volume":"42","author":"Hainsworth","year":"2019","journal-title":"Diabetes Care"},{"issue":"6","key":"2026092511121457600_dgag380-B8","article-title":"Enhanced glucose control for preventing and treating diabetic neuropathy","volume":"2012","author":"Callaghan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"2026092511121457600_dgag380-B9","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.2337\/dc21-2298","article-title":"Association of estimated time-in-range capillary glucose levels versus HbA1c with progression of microvascular complications in the diabetes control and complications trial","volume":"45","author":"Lachin","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"2026092511121457600_dgag380-B10","doi-asserted-by":"crossref","first-page":"e2221","DOI":"10.1210\/clinem\/dgac034","article-title":"Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring","volume":"107","author":"Yapanis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026092511121457600_dgag380-B11","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00125-024-06171-y","article-title":"The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study","volume":"67","author":"De Meulemeester","year":"2024","journal-title":"Diabetologia"},{"issue":"4","key":"2026092511121457600_dgag380-B12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1089\/dia.2023.0486","article-title":"Time in range is associated with incident diabetic retinopathy in adults with type 1 diabetes: a longitudinal study","volume":"26","author":"Shah","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"2026092511121457600_dgag380-B13","doi-asserted-by":"crossref","first-page":"e1146","DOI":"10.1210\/clinem\/dgaf544","article-title":"Time in range and incident diabetic retinopathy: clinical and economic evidence from real-world type 1 diabetes care","volume":"111","author":"Chen","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026092511121457600_dgag380-B14","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc17-1624","article-title":"Standardizing clinically meaningful outcome measures beyond HbA(1c) for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of A, the American A, the A, JDRF inteArnational, the Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange","volume":"40","author":"Agiostratidou","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"2026092511121457600_dgag380-B15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1210\/jc.2017-02498","article-title":"Effect of continuous glucose monitoring on glycemic control, acute admissions, and quality of life: a real-world study","volume":"103","author":"Charleer","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026092511121457600_dgag380-B16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2337\/dc19-1610","article-title":"Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study","volume":"43","author":"Charleer","year":"2020","journal-title":"Diabetes Care"},{"issue":"10291","key":"2026092511121457600_dgag380-B17","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0140-6736(21)00789-3","article-title":"Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial","volume":"397","author":"Visser","year":"2021","journal-title":"Lancet"},{"key":"2026092511121457600_dgag380-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111690","article-title":"Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting","volume":"212","author":"Brett McQueen","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"2026092511121457600_dgag380-B19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"2026092511121457600_dgag380-B20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference: understanding AIC and BIC in model selection","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociol Methods Res"},{"key":"2026092511121457600_dgag380-B21","doi-asserted-by":"crossref","unstructured":"Sabbe A, Bochanen N, Van den Broucke A, et al \u00a02026. Supplemental Material for: Association between worsening time in range and microvascular complications in type 1 diabetes: real-world 5-year study. Deposited 11 September 2026. doi:10.5281\/zenodo.22711363.","DOI":"10.1210\/clinem\/dgag380"},{"issue":"8","key":"2026092511121457600_dgag380-B22","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2026092511121457600_dgag380-B23","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.2337\/dc25-S007","article-title":"7. Diabetes technology: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"4","key":"2026092511121457600_dgag380-B24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"2026092511121457600_dgag380-B25","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J Clin Epidemiol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag380\/71101992\/dgag380.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag380\/71101992\/dgag380.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:12:20Z","timestamp":1790349140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article\/doi\/10.1210\/clinem\/dgag380\/8798718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag380","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"dgag380"}}